ArticleOncogene2018

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.

H Yamaguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.